| Business Summary |
| A biopharmaceutical company, which is focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. |
| General Information |
45 Hartell Avenue
Lexington, MA 02421
|
| www.syntapharma.com |
| Industry : Drugs |
| Sector: Health Care |
| Employees: 129 |
| CEO: Dr. Safi R. Bahcall, Ph. |
| Short Interest |
| Current Month (Mil) |
0.70 |
| Previous Month (Mil) |
0.69 |
| Short Interest Ratio (Days) |
11.70 |
| Management Effectiveness |
| Return on Equity |
195.00 |
| Return on Assets |
104.50 |
| Return on Investments |
188.00 |
| Profitability |
| Gross Margin |
n.a. |
| EBIT Margin |
43.40 |
| Profit Margin |
42.90 |
Connect with TheStreet